论文部分内容阅读
为了考核新生儿接种国产重组(酵母)乙型肝炎(乙肝)疫苗后的免疫效果,并与血源乙肝疫苗效果比较。对1997年出生并接种重组(酵母)乙肝疫苗的新生儿隔年随访一次,采血检测乙肝病毒表面抗原(HBsAg),乙肝病毒表面抗体(抗-HBs)和乙肝病毒核心抗体(抗-HBc),1998年以后对乙肝免疫人群开展急性乙肝发病监测。显示五年期间3次随访检测HBsAg阳性率平均为1.5%,较免前本底的HBsAg阳性率呈较大幅度下降,疫苗保护率为83%(95%可信区间为76.97%~89.02%),无论母亲HBsAg阳性或阴性,使用不同乙肝疫苗的儿童HBsAg阳性率没有统计学差异。接受重组(酵母)乙肝疫苗免疫的对象中,无一例急性乙肝病例报告。重组(酵母)乙肝疫苗有较好的近期保护效果和免疫原性,与以前使用血源乙肝疫苗效果相当。
In order to assess the immunization effect of newborns vaccinated domestic recombinant (yeast) hepatitis B (hepatitis B) vaccine, and compared with the effect of blood-borne hepatitis B vaccine. Blood samples were collected for hepatitis B virus surface antigen (HBsAg), hepatitis B virus surface antibody (anti-HBs) and hepatitis B virus core antibody (anti-HBc) in 1998, followed up every other year for newborns born in 1997 and vaccinated with recombinant (yeast) Years after the hepatitis B immune crowd to carry out monitoring of acute hepatitis B incidence. The results showed that the positive rate of HBsAg in three follow-ups during the five-year follow-up was 1.5%, which was significantly lower than that of the pre-ex background. The vaccine protection rate was 83% (95% CI: 76.97% -89.02%) There was no significant difference in the positive rate of HBsAg between children with different hepatitis B vaccines, regardless of the mother’s HBsAg positive or negative. None of the subjects receiving recombinant (yeast) hepatitis B vaccine reported acute hepatitis B cases. Recombinant (yeast) hepatitis B vaccine has good recent protective effect and immunogenicity, with the previous use of blood-borne hepatitis B vaccine effect.